XBiotech Inc. (XBIT) News
Filter XBIT News Items
XBIT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest XBIT News From Around the Web
Below are the latest news stories about XBiotech Inc that investors may wish to consider to help them evaluate XBIT as an investment opportunity.
XBiotech Inks Clinical Manufacturing DealXBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & JohnsonAUSTIN, Texas, Feb. 02, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBiotech in December 2019. XBiotech discovers and develops therap |
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQNatrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) enrolled the first patient in a randomized, double-blind, placebo-controlled clinical study to evaluate safety and pharmacokinetics of Natrunix-SQ. Natrunix-SQ targets a crucial inflammatory pathway involved in pain and joint destruction in various forms of arthritis. XBiotech be |
Moderna CEO talks Omicron booster shots, 2022 COVID-19 vaccine sales forecasts, global vaccinationModerna CEO Stéphane Bancel joins Yahoo Finance’s Anjalee Khemlani to discuss the development of an Omicron-specific booster shot, global vaccination efforts, data on the effectiveness of the COVID-19 vaccine, and raised forecasts for vaccine sales and production in 2022. |
New COVID-19 vaccine that covers Omicron ‘will be ready in March,’ Pfizer CEO saysPfizer CEO Albert Bourla joins Yahoo Finance’s Anjalee Khemlani to discuss the development of a new COVID-19 vaccine that will include protection against Omicron, vaccine production, and the outlook for an Omicron-specific booster. |
Do Insiders Own Lots Of Shares In XBiotech Inc. (NASDAQ:XBIT)?A look at the shareholders of XBiotech Inc. ( NASDAQ:XBIT ) can tell us which group is most powerful. Large companies... |
FDA Approves XBiotech’s IND in RheumatologyLaunching Novel True Human Antibody Therapy Natrunix™ to Treat RheumatologyAUSTIN, Texas, Dec. 13, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to commence clinical development of Natrunix, the Company’s novel True Human™ antibody candidate therapy for treating rheumatological disease. The authorization, granted based on the Company’s investigational new drug (IND) application, allows the company to begin c |
Wells Fargo & Company MN Sells 17,033 Shares of XBiotech Inc. (NASDAQ:XBIT)Wells Fargo & Company MN reduced its stake in XBiotech Inc. (NASDAQ:XBIT) by 7.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 210,484 shares of the biopharmaceutical companys stock after selling 17,033 shares during the period. Wells Fargo & Company [] |
XBiotech Inc.: XBiotech to Launch Novel Candidate Therapy for StrokeCompany Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) |
XBiotech to Launch Novel Candidate Therapy for StrokeCompany Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke |
Citigroup Inc. Has $48,000 Holdings in XBiotech Inc. (NASDAQ:XBIT)Citigroup Inc. grew its position in XBiotech Inc. (NASDAQ:XBIT) by 72.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,881 shares of the biopharmaceutical companys stock after purchasing an additional 1,211 shares during the period. Citigroup Inc.s holdings in XBiotech [] |